These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 39335506)

  • 1. Comparison of the Effectiveness of Vedolizumab and Ustekinumab in Patients with Ulcerative Colitis: A Real-World Retrospective Study.
    Nomura K; Shibuya T; Odakura R; Haraikawa M; Ishino H; Orikasa M; Omori M; Koma M; Ito K; Maruyama T; Nomura O; Ishikawa D; Hojo M; Nagahara A
    Biomedicines; 2024 Sep; 12(9):. PubMed ID: 39335506
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world clinical outcomes and healthcare costs in patients with Crohn's disease treated with vedolizumab versus ustekinumab in the United States.
    Chiorean M; Jiang J; Candela N; Chen G; Romdhani H; Latremouille-Viau D; Shi S; Bungay R; Guerin A; Fan T
    Curr Med Res Opin; 2024 May; 40(5):877-885. PubMed ID: 38586979
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world effectiveness of ustekinumab and vedolizumab in TNF-exposed pediatric patients with ulcerative colitis.
    Patel PV; Zhang A; Bhasuran B; Ravindranath VG; Heyman MB; Verstraete SG; Butte AJ; Rosen MJ; Rudrapatna VA;
    J Pediatr Gastroenterol Nutr; 2024 May; 78(5):1126-1134. PubMed ID: 38482890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness and Persistency of Ustekinumab Treatment for Ulcerative Colitis: A Phoenix retrospective Cohort Study.
    Ando K; Fujiya M; Ueno N; Ito T; Maemoto A; Nasuno M; Tanaka H; Sakurai K; Katsurada T; Orii F; Ashida T; Motoya S; Kazama T; Yokoyama Y; Hirayama D; Nakase H
    Crohns Colitis 360; 2024 Apr; 6(2):otae024. PubMed ID: 38711858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ustekinumab is associated with superior treatment persistence but not with higher remission rates
    Bacsur P; Matuz M; Resál T; Miheller P; Szamosi T; Schäfer E; Sarlós P; Iliás Á; Szántó K; Rutka M; Bálint A; Milassin Á; Fábián A; Bor R; Szepes Z; Molnár T; Farkas K
    Therap Adv Gastroenterol; 2022; 15():17562848221144349. PubMed ID: 36600684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness and Safety of Ustekinumab for Ulcerative Colitis: A Brazilian Multicentric Observational Study.
    Parra RS; Chebli JMF; de Azevedo MFC; Chebli LA; Zabot GP; Cassol OS; de Sá Brito Fróes R; Santana GO; Lubini M; Magro DO; Imbrizi M; Moraes ACDS; Teixeira FV; Alves Junior AJT; Gasparetti Junior NLT; da Costa Ferreira S; Queiroz NSF; Kotze PG; Féres O
    Crohns Colitis 360; 2024 Apr; 6(2):otae023. PubMed ID: 38681979
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effectiveness of ustekinumab and vedolizumab as third-line biologic therapy in patients with Crohn's disease.
    Macaluso FS; Grova M; Saladino M; Cappello M; Demarzo MG; Privitera AC; Giangreco E; Garufi S; Renna S; Casà A; Ventimiglia M; Fries W; Orlando A;
    Dig Liver Dis; 2023 Apr; 55(4):471-477. PubMed ID: 36127230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Remission Factors for Ustekinumab Treatment of Ulcerative Colitis: A Multicenter Retrospective Study of Real-World Data in Japan.
    Omori M; Shibuya T; Ishino H; Fukuo Y; Odakura R; Koma M; Maruyama T; Ito K; Haraikawa M; Nomura K; Yano S; Nomura O; Ishikawa D; Hojo M; Osada T; Nagahara A
    Biomedicines; 2024 May; 12(5):. PubMed ID: 38791081
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of Ustekinumab and Vedolizumab Among Postoperative Crohn's Disease Patients as Postoperative Prophylaxis and Rescue Therapy: Real-world Data.
    Ertem FU; Rivers CR; Ghaffari AA; Watson AR; Tang G; Schwartz M; Johnston E; Barrie A; Harrison J; Dueker JM; Hartman D; Binion DG
    Inflamm Bowel Dis; 2024 Jul; ():. PubMed ID: 38953641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term outcomes and predictors of vedolizumab persistence in ulcerative colitis.
    Gros B; Ross H; Nwabueze M; Constantine-Cooke N; Derikx LAAP; Lyons M; O'Hare C; Noble C; Arnott ID; Jones GR; Lees CW; Plevris N
    Therap Adv Gastroenterol; 2024; 17():17562848241258372. PubMed ID: 39086990
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of ustekinumab vs. advanced therapies for the treatment of moderately to severely active ulcerative colitis: a systematic review and network meta-analysis.
    Welty M; Mesana L; Padhiar A; Naessens D; Diels J; van Sanden S; Pacou M
    Curr Med Res Opin; 2020 Apr; 36(4):595-606. PubMed ID: 31960724
    [No Abstract]   [Full Text] [Related]  

  • 12. Real-world effectiveness and safety of ustekinumab and vedolizumab in elderly patients with Crohn's disease.
    Garg R; Aggarwal M; Mohammed A; Achkar JP; Lashner B; Philpott J; Cohen B; Qazi T; Rieder F; Regueiro M; Click B
    Indian J Gastroenterol; 2023 Oct; 42(5):718-723. PubMed ID: 37523059
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early Clinical Remission Is a Predictor of Long-Term Remission with the Use of Vedolizumab for Ulcerative Colitis.
    Haga K; Shibuya T; Osada T; Sato S; Fukuo Y; Kobayashi O; Yamada T; Asaoka D; Ito K; Nomura K; Haraikawa M; Nomura O; Fukushima H; Murakami T; Ishikawa D; Hojo M; Nagahara A
    Biomedicines; 2022 Oct; 10(10):. PubMed ID: 36289788
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-World Effectiveness and Risk Factors for Discontinuation of Ustekinumab in Ulcerative Colitis.
    Uchida G; Nakamura M; Yamamura T; Maeda K; Sawada T; Ishikawa E; Furukawa K; Iida T; Mizutani Y; Yamao K; Ishikawa T; Ishizu Y; Honda T; Ishigami M; Kawashima H
    Inflamm Intest Dis; 2023 Oct; 8(2):60-68. PubMed ID: 37901340
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effectiveness of vedolizumab in advanced therapy-experienced ulcerative colitis patients: Real world data from the Inflammatory Bowel Disease of the Middle East (IBD-ME) Registry group.
    Azzam N; Alharbi O; Altuwaijri M; Alruthia Y; Alfarhan H; Alshankiti S; Nafisah F; Ajlan Q; Aljebreen A; Almadi M; Mosli MH
    Saudi J Gastroenterol; 2024 Sep; ():. PubMed ID: 39291466
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment persistence of ustekinumab and vedolizumab in IBD patients is independent of prior immunogenicity to anti-TNFs: a retrospective study.
    Blesl A; Petritsch W; Binder L; Fürst S; Wenzl H; Baumann-Durchschein F; Kump P; Högenauer C
    Scand J Gastroenterol; 2022 Nov; 57(11):1327-1330. PubMed ID: 35732583
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Machine learning using clinical data at baseline predicts the medium-term efficacy of ustekinumab in patients with ulcerative colitis.
    Morikubo H; Tojima R; Maeda T; Matsuoka K; Matsuura M; Miyoshi J; Tamura S; Hisamatsu T
    Sci Rep; 2024 Feb; 14(1):4386. PubMed ID: 38388662
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative efficacy and safety of subcutaneous infliximab and vedolizumab in patients with Crohn's disease and ulcerative colitis included in randomised controlled trials.
    Peyrin-Biroulet L; Arkkila P; Armuzzi A; Danese S; Ferrante M; Jordi Guardiola ; Jahnsen J; Louis E; Lukáš M; Reinisch W; Roblin X; Smith PJ; Kwon T; Kim J; Yoon S; Kim DH; Atreya R
    BMC Gastroenterol; 2024 Mar; 24(1):121. PubMed ID: 38539103
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic sequencing in inflammatory bowel disease: Determining the optimal position of vedolizumab for long-term Crohn's disease control using real-world evidence.
    Louis E; Litkiewicz M; Agboton C; Armuzzi A
    United European Gastroenterol J; 2024 Jun; 12(5):574-584. PubMed ID: 38717013
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prior Immunogenicity to Anti-TNF Biologics Is Not Associated with Increased Anti-drug Antibodies to Vedolizumab or Ustekinumab.
    Costable NJ; Borman ZA; Ji J; Dubinsky MC; Ungaro RC
    Dig Dis Sci; 2022 Jun; 67(6):2480-2484. PubMed ID: 34021427
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.